Brivanib, a Dual FGF/VEGF Inhibitor, Is Active Both First and Second Line against Mouse Pancreatic Neuroendocrine Tumors Developing Adaptive/Evasive Resistance to VEGF Inhibition
(Q24616631)
scientific article published on May 27, 2011
scientific article published on May 27, 2011
Language: